drugset
drugset / Trial / NCT00135031

Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome

NCT00135031 ↗

Phase 3 Completed 362 enrolled Procter and Gamble Alimentary Health Ltd · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine the dose-ranging efficacy and safety profile of encapsulated Bifidobacterium infantis 35624 in female subjects with irritable bowel syndrome (IBS).

Timeline

Start
2004-01
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifidobacterium infantis 35624 Other / unclassified — —

Indications

irritable bowel syndrome